Dapagliflozin Cancer Signal Weighs Heavily In FDA Panel's Negative Vote

The Endocrinologic and Metabolic Drugs Advisory Committee votes 9-6 against approval of the first-in-class SGLT-2 inhibitor, with panelists citing the need for more pre-approval data on the risk of bladder and breast cancer with the diabetes drug.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet